CervoMed (CRVO) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rockwell Medical (RMTI) has outperformed CervoMed (CRVO) over the past year, losing 34.6% versus a loss of 83.6%. Over five years, RMTI leads with a -88.0% price change compared with -95.0% for CRVO. Rockwell Medical is the larger company by market cap ($23.1 million vs $22.1 million), about 1.0 times the size.
Rockwell Medical converts more of its revenue into profit, with a net margin of -7.7% versus -673.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | RMTI |
|---|---|---|
| Share price | $1.46 | $5.82 |
| Market cap | $22.09M | $23.12M |
| 1-day change | +9.77% | -7.03% |
| YTD return | -81.52% | -29.88% |
| 1-year return | -83.56% | -34.61% |
| 5-year return | -95.01% | -87.98% |
| Forward P/E | — | 83.14 |
| EPS (TTM) | $-2.65 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.01M | $69.26M |
| Revenue growth (YoY) | -58.86% | -31.76% |
| Net income (latest FY) | $-26.97M | $-5.31M |
| Gross margin | — | 16.89% |
| Operating margin | -706.22% | -6.77% |
| Net margin | -673.06% | -7.67% |
| 52-week high | $10.00 | $12.90 |
| 52-week low | $1.27 | $4.89 |
| Distance from 52-week high | -85.40% | -54.88% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +954.79% | +243.64% |
| Average volume | 489.10K | 25.91K |
| Shares outstanding | 15.13M | 3.97M |
| Employees | 15 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed CRVO by 49.0 percentage points over the past year.
- Rockwell Medical is more profitable, keeping -7.7 cents of every revenue dollar as net income versus -673.1 cents for CervoMed.
- Rockwell Medical grew revenue faster in its latest fiscal year (-31.76% vs -58.86%).
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
CRVO vs RMTI FAQ
Which is bigger, CervoMed or Rockwell Medical?
Rockwell Medical (RMTI) is larger, with a market capitalization of $23.12M compared with $22.09M for CervoMed (CRVO).
Which stock has performed better over the past year, CRVO or RMTI?
RMTI returned -34.61% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.